BioLamina

1 known investors

BioLamina develops full-length human recombinant laminin products (Biolaminin) that provide cell-type-specific substrates for 2D and 3D cell culture, supporting stem cell research and clinical cell therapy development. Its animal-origin-free, regulatory-compliant products serve researchers and cell therapy developers working on experimental standardization and clinical applications.

BiotechHealthtechNew Materials